ESPR — Esperion Therapeutics, Inc.

Summary of Esperion Therapeutics Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $168.4 million for Q4 2025, a 144% increase year-over-year.
• U.S. Net Product Revenue: $43.7 million, up 38% from $31.6 million in Q4 2024.
• Collaboration Revenue: $124.7 million, a 232% increase, driven by a $90 million one-time payment from Otsuka.
• Cash Position: Ended 2025 with $167.9 million in cash and reduced debt by $55 million.
• Operating Expenses: Q4 R&D expenses were $13.9 million (up 26% YoY), and SG&A expenses were $41.4 million (up 12% YoY), primarily due to increased legal costs.

2. Strategic Updates and Business Highlights

• Vision 2040: Introduced as a long-term strategy focusing on expanding the company’s product portfolio.
• Acquisition of Corstasis Therapeutics: Aimed at enhancing Esperion's offerings with Enbumyst, an intranasal diuretic for heart failure, expected to close in Q2 2026.
• Bempedoic Acid Franchise Growth: Strong prescription growth and expanded payer coverage, particularly targeting statin-intolerant patients.
• International Expansion: Significant growth in Europe and Japan, with Daiichi Sankyo reporting a 51% increase in royalty revenue and Otsuka launching NEXLETOL in Japan.

3. Forward Guidance and Outlook

• 2026 Expectations: Anticipate continued momentum in the bempedoic acid franchise and expect favorable positioning in upcoming U.S. dyslipidemia guidelines.
• Operating Expense Guidance: Projected to be between $225 million and $255 million for 2026, including $15 million in non-cash stock compensation expenses.
• Triple Combination Programs: Expected to complete clinical and regulatory requirements for commercialization by 2027.

4. Bad News, Challenges, or Points of Concern

• Legal Costs: Increased SG&A expenses due to ongoing legal issues related to ANDA litigation.
• Competitive Pressures: Potential new competitors entering the market could impact pricing and market share, although management expressed confidence in their product's outcomes data.
• Guidance on Collaboration Revenue: While collaboration revenue is expected to grow, there are uncertainties due to the absence of significant milestone payments in 2026.

5. Notable Q&A Insights

• Corstasis Acquisition: Management confirmed readiness for product launch and highlighted the importance of the auto-injector development.
• ACC Guidelines: Anticipated release of U.S. guidelines before the ACC conference, with expectations of positive impacts on prescribing behavior.
• Sales Force Strategy: Plans to modestly expand the sales team post-acquisition to ensure adequate coverage for new products.
• Triple Combination Therapy: Management believes it will enhance the bempedoic acid franchise without muddying the message around statin intolerance.

Overall, Esperion reported a strong financial performance in 2025, with strategic initiatives that position the company for future growth, despite facing some legal and competitive challenges.